Cargando…
Combination of peroxisome proliferator–activated receptor gamma and retinoid X receptor agonists induces sodium/iodide symporter expression and inhibits cell growth of human thyroid cancer cells
Thyroid tumors are the most frequent neoplasm of the endocrine system. The major treatment is surgical intervention followed by radioiodine therapy. The sodium/iodide symporter (NIS) has positive expression in thyroid carcinomas with good prognoses and plays a critical role in radioiodine therapy re...
Autores principales: | Chen, Jui-Yu, Wang, Jane-Jen, Lee, Hsin-Chen, Chi, Chin-Wen, Lee, Chen-Hsen, Hsu, Yi-Chiung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526568/ https://www.ncbi.nlm.nih.gov/pubmed/33009242 http://dx.doi.org/10.1097/JCMA.0000000000000389 |
Ejemplares similares
-
Dimerization of the Sodium/Iodide Symporter
por: Thompson, Rebecca J., et al.
Publicado: (2019) -
Evaluation of Lentiviral-Mediated Expression of Sodium Iodide Symporter in Anaplastic Thyroid Cancer and the Efficacy of In Vivo Imaging and Therapy
por: Ke, Chien-Chih, et al.
Publicado: (2011) -
Retinoid X receptor and peroxisome proliferator-activated receptor-gamma agonists cooperate to inhibit matrix metalloproteinase gene expression
por: Burrage, Peter S, et al.
Publicado: (2008) -
Sodium iodide symporter-targeted gene therapy in glioblastoma
por: Nicola, Juan Pablo, et al.
Publicado: (2023) -
Tumor microenvironment affects exogenous sodium/iodide symporter expression
por: Castillo-Rivera, Fabio, et al.
Publicado: (2020)